Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 5492-5496, November 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Du, W.
Right arrow Articles by Prendergast, G. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Du, W.
Right arrow Articles by Prendergast, G. C.
[Cancer Research 59, 5492-5496, November 1, 1999]
© 1999 American Association for Cancer Research

Advances in Brief

Geranylgeranylated RhoB Mediates Suppression of Human Tumor Cell Growth by Farnesyltransferase Inhibitors1

Wei Du2 and George C. Prendergast2,,3

The Wistar Institute, Philadelphia, Pennsylvania 19104

Farnesyltransferase inhibitors (FTIs) are in clinical trials, but their mechanism of action is not fully understood. We have shown that FTI treatment rapidly elevates the level of geranylgeranylated RhoB in cells and that this event is sufficient to inhibit cell cycle transit and reverse malignant transformation without affecting normal cells. However, because these observations were made in rodent fibroblast models in which transformation was driven by defined genetic alterations, it remained to be established whether RhoB-GG was relevant to the antineoplastic effects of FTIs in human epithelial tumor cells with diverse genetic backgrounds. In this study, we show that elevated levels of RhoB-GG are sufficient to block the proliferation of FTI-sensitive but not FTI-resistant human carcinoma cells. RhoB-GG induced the cell cycle kinase inhibitor p21WAF1 in a p53-dependent manner, similar to FTI treatment, but this event was dispensable because RhoB-GG could still inhibit the growth of p53-null cells that lacked p21WAF1 activation. Consistent with actions beyond G1-phase arrest, certain cell lines exhibited accumulation in G2-M phase or an increased apoptotic index in response to RhoB-GG. We concluded that RhoB-GG suppressed human tumor cell proliferation by more than one mechanism and that it promoted apoptosis as well as inhibited cell cycle transit in malignant epithelial cells. These findings suggest how FTIs suppress the growth of human tumor cells that lack Ras mutations.




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
T. T. G. Ho, S. D. Merajver, C. M. Lapiere, B. V. Nusgens, and C. F. Deroanne
RhoA-GDP Regulates RhoB Protein Stability: POTENTIAL INVOLVEMENT OF RhoGDI{alpha}
J. Biol. Chem., August 1, 2008; 283(31): 21588 - 21598.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
E. Sandilands, V. G. Brunton, and M. C. Frame
The membrane targeting and spatial activation of Src, Yes and Fyn is influenced by palmitoylation and distinct RhoB/RhoD endosome requirements
J. Cell Sci., August 1, 2007; 120(15): 2555 - 2564.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. F. Goemans, C. M. Zwaan, A. Harlow, A. H. Loonen, B. E. S. Gibson, K. Hahlen, D. Reinhardt, U. Creutzig, M. C. Heinrich, and G. J. L. Kaspers
In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets
Blood, November 15, 2005; 106(10): 3532 - 3537.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Pan and S.-C. J. Yeung
Recent Advances in Understanding the Antineoplastic Mechanisms of Farnesyltransferase Inhibitors
Cancer Res., October 15, 2005; 65(20): 9109 - 9112.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
W-B Zhong, Y-C Liang, C-Y Wang, T-C Chang, and W-S Lee
Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling
Endocr. Relat. Cancer, September 1, 2005; 12(3): 615 - 629.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
N. M.G.M. Appels, J. H. Beijnen, and J. H.M. Schellens
Development of Farnesyl Transferase Inhibitors: A Review
Oncologist, September 1, 2005; 10(8): 565 - 578.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. Maeda, I. Matsuoka, T. Iwamoto, H. Kurose, and J. Kimura
Down-Regulation of Na+/Ca2+ Exchanger by Fluvastatin in Rat Cardiomyoblast H9c2 Cells: Involvement of RhoB in Na+/Ca2+ Exchanger mRNA Stability
Mol. Pharmacol., August 1, 2005; 68(2): 414 - 420.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
L. M. Bruzek, J. N. Poynter, S. H. Kaufmann, and A. A. Adjei
Characterization of a Human Carcinoma Cell Line Selected for Resistance to the Farnesyl Transferase Inhibitor 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336)
Mol. Pharmacol., August 1, 2005; 68(2): 477 - 486.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
M. Fernandez-Borja, L. Janssen, D. Verwoerd, P. Hordijk, and J. Neefjes
RhoB regulates endosome transport by promoting actin assembly on endosomal membranes through Dia1
J. Cell Sci., June 15, 2005; 118(12): 2661 - 2670.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Pan, M. She, Z.-X. Xu, L. Sun, and S.-C. J. Yeung
Farnesyltransferase Inhibitors Induce DNA Damage via Reactive Oxygen Species in Human Cancer Cells
Cancer Res., May 1, 2005; 65(9): 3671 - 3681.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Deacu, Y. Mori, F. Sato, J. Yin, A. Olaru, A. Sterian, Y. Xu, S. Wang, K. Schulmann, A. Berki, et al.
Activin Type II Receptor Restoration in ACVR2-Deficient Colon Cancer Cells Induces Transforming Growth Factor-{beta} Response Pathway Genes
Cancer Res., November 1, 2004; 64(21): 7690 - 7696.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. L. Moulder, J. J. Mahany, R. Lush, C. Rocha-Lima, M. Langevin, K. J. Ferrante, L. M. Bartkowski, S. M. Kajiji, D. A. Noe, S. Paillet, et al.
A Phase I Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients with Advanced Malignant Tumors
Clin. Cancer Res., November 1, 2004; 10(21): 7127 - 7135.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
M. Wherlock, A. Gampel, C. Futter, and H. Mellor
Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase
J. Cell Sci., July 1, 2004; 117(15): 3221 - 3231.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
K. Jiang, J. Sun, J. Cheng, J. Y. Djeu, S. Wei, and S. Sebti
Akt Mediates Ras Downregulation of RhoB, a Suppressor of Transformation, Invasion, and Metastasis
Mol. Cell. Biol., June 15, 2004; 24(12): 5565 - 5576.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. P. Ryan, J. P. Eder Jr., T. Puchlaski, M. V. Seiden, T. J. Lynch, C. S. Fuchs, P. C. Amrein, D. Sonnichsen, J. G. Supko, and J. W. Clark
Phase I Clinical Trial of the Farnesyltransferase Inhibitor BMS-214662 Given as a 1-Hour Intravenous Infusion in Patients with Advanced Solid Tumors
Clin. Cancer Res., April 1, 2004; 10(7): 2222 - 2230.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
K. Wennerberg and C. J. Der
Rho-family GTPases: it's not only Rac and Rho (and I like it)
J. Cell Sci., March 15, 2004; 117(8): 1301 - 1312.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. M. McHardy, R. Sinotte, A. Troussard, C. Sheldon, J. Church, D. E. Williams, R. J. Andersen, S. Dedhar, M. Roberge, and C. D. Roskelley
The Tumor Invasion Inhibitor Dihydromotuporamine C Activates RHO, Remodels Stress Fibers and Focal Adhesions, and Stimulates Sodium-Proton Exchange
Cancer Res., February 15, 2004; 64(4): 1468 - 1474.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. J. Fiordalisi, R. L. Johnson II, C. A. Weinbaum, K. Sakabe, Z. Chen, P. J. Casey, and A. D. Cox
High Affinity for Farnesyltransferase and Alternative Prenylation Contribute Individually to K-Ras4B Resistance to Farnesyltransferase Inhibitors
J. Biol. Chem., October 24, 2003; 278(43): 41718 - 41727.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. B. Brunner, S. M. Hahn, A. K. Gupta, R. J. Muschel, W. G. McKenna, and E. J. Bernhard
Farnesyltransferase Inhibitors: An Overview of the Results of Preclinical and Clinical Investigations
Cancer Res., September 15, 2003; 63(18): 5656 - 5668.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Selleri, J. P. Maciejewski, N. Montuori, P. Ricci, V. Visconte, B. Serio, L. Luciano, and B. Rotoli
Involvement of nitric oxide in farnesyltransferase inhibitor-mediated apoptosis in chronic myeloid leukemia cells
Blood, August 15, 2003; 102(4): 1490 - 1498.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H.-L. Yang, J.-X. Pan, L. Sun, and S.-C. J. Yeung
p21 Waf-1 (Cip-1) Enhances Apoptosis Induced by Manumycin and Paclitaxel in Anaplastic Thyroid Cancer Cells
J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 763 - 772.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. R. Mattingly, R. A. Gibbs, R. E. Menard, and J. J. Reiners Jr.
Potent Suppression of Proliferation of A10 Vascular Smooth Muscle Cells by Combined Treatment with Lovastatin and 3-Allylfarnesol, an Inhibitor of Protein Farnesyltransferase
J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 74 - 81.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. A. Ellis, M. D. Vos, H. Howell, T. Vallecorsa, D. W. Fults, and G. J. Clark
Rig is a novel Ras-related protein and potential neural tumor suppressor
PNAS, July 23, 2002; 99(15): 9876 - 9881.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Sharma, N. Kemeny, D. P. Kelsen, D. Ilson, E. O'Reilly, S. Zaknoen, C. Baum, P. Statkevich, E. Hollywood, Y. Zhu, et al.
A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan
Ann. Onc., July 1, 2002; 13(7): 1067 - 1071.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. B. Lobell, D. Liu, C. A. Buser, J. P. Davide, E. DePuy, K. Hamilton, K. S. Koblan, Y. Lee, S. Mosser, S. L. Motzel, et al.
Preclinical and Clinical Pharmacodynamic Assessment of L-778,123, a Dual Inhibitor of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Type-I
Mol. Cancer Ther., July 1, 2002; 1(9): 747 - 758.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Adnane, C. Muro-Cacho, L. Mathews, S. M. Sebti, and T. Munoz-Antonia
Suppression of Rho B Expression in Invasive Carcinoma from Head and Neck Cancer Patients
Clin. Cancer Res., July 1, 2002; 8(7): 2225 - 2232.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Crul, G. J. de Klerk, M. Swart, L. J. van't Veer, D. de Jong, L. Boerrigter, P. A. Palmer, C. J. Bol, H. Tan, G. C. de Gast, et al.
Phase I Clinical and Pharmacologic Study of Chronic Oral Administration of the Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer
J. Clin. Oncol., June 1, 2002; 20(11): 2726 - 2735.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Adnane, E. Seijo, Z. Chen, F. Bizouarn, M. Leal, S. M. Sebti, and T. Munoz-Antonia
RhoB, Not RhoA, Represses the Transcription of the Transforming Growth Factor beta Type II Receptor by a Mechanism Involving Activator Protein 1
J. Biol. Chem., March 1, 2002; 277(10): 8500 - 8507.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Pan, G. Xu, and S.-C. J. Yeung
Cytochrome c Release Is Upstream to Activation of Caspase-9, Caspase-8, and Caspase-3 in the Enhanced Apoptosis of Anaplastic Thyroid Cancer Cells Induced by Manumycin and Paclitaxel
J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4731 - 4740.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. A. Adjei
Blocking Oncogenic Ras Signaling for Cancer Therapy
J Natl Cancer Inst, July 18, 2001; 93(14): 1062 - 1074.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. A. Adjei, J. N. Davis, L. M. Bruzek, C. Erlichman, and S. H. Kaufmann
Synergy of the Protein Farnesyltransferase Inhibitor SCH66336 and Cisplatin in Human Cancer Cell Lines
Clin. Cancer Res., May 1, 2001; 7(5): 1438 - 1445.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. Xu, J. Pan, C. Martin, and S.-C. J. Yeung
Angiogenesis Inhibition in the in Vivo Antineoplastic Effect of Manumycin and Paclitaxel against Anaplastic Thyroid Carcinoma
J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1769 - 1777.
[Abstract] [Full Text]

Home page
 Mol. Cell. Biol.Home page
A.-x. Liu, W. Du, J.-P. Liu, T. M. Jessell, and G. C. Prendergast
RhoB Alteration Is Necessary for Apoptotic and Antineoplastic Responses to Farnesyltransferase Inhibitors
Mol. Cell. Biol., August 15, 2000; 20(16): 6105 - 6113.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
H. E. Huber, R. G. Robinson, A. Watkins, D. D. Nahas, M. T. Abrams, C. A. Buser, R. B. Lobell, D. Patrick, N. J. Anthony, C. J. Dinsmore, et al.
Anions Modulate the Potency of Geranylgeranyl-Protein Transferase I Inhibitors
J. Biol. Chem., June 29, 2001; 276(27): 24457 - 24465.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.